To describe the clinical characteristics and define the indicators that best predict survival in patients with bone métastases from thyroid carcinomas. We collected data from medical records of 146 patients with documented bone métastases from thyroid carcinoma seen at our medical center over a 38-year period. Univariate and multivariate analyses of prognostic indicators for survival were performed. Bone métastases were present at the initial diagnosis in 47% of patients. Vertebrae (29%), pelvis (22%), ribs (17%), and femur (11%) were the most common sites of métastases. Multiple lesions were present in 53% of the cases. The overall 10-year survival rate from the time of diagnosis of thyroid cancer was 35%, and from diagnosis of initial bone metastasis was 13%. By univariate analysis from the time of the initial bone metastasis, radioiodine uptake by skeletal métastases, the absence of nonosseous métastases and treatment with radioiodine were significant prognostic factors. By multivariate analysis, radioiodine uptake by skeletal métastases and the absence of nonosseous métastases were independent favorable prognostic variables for survival. In a subgroup of patients in which histologie specimens were available and were reviewed, Hürthle cell carcinoma was the most favorable histologie subtype for survival with the undifferentiated subtype being the worst. The spread of thyroid carcinoma to bone is more common in patients over 45 years of age, is usually symptomatic, and is often multicentric. Overall survival is best in those whose lesions concentrate radioactive iodine and those who have no nonosseous métastases.
Introduction
Carcinoma of the thyroid gland is one of the most curable cancers (1) , yet more than 1,000 individuals die of it in the United States alone each year. Patients with distant métastases, especially to bone, have a markedly reduced survival (2) (3) (4) (5) (6) (7) (8) (9) . At the time of initial diagnosis, l%-3% of patients with thyroid cancer have distant métastases whereas another 7%-23% will develop distant métastases during the course of their disease (2, (5) (6) (7) (8) (10) (11) (12) . Bone métastases are diagnosed clinically in 4%-13% of patients with differentiated thyroid cancer (9, 13, 14) . Several smaller reviews of patients with thyroid cancer metastatic to bone have suggested that skeletal involvement is difficult to treat and is associated with a poor prognosis (5, 8, 14, 15) . The (Table 1) , with respect to survival time from diagnosis of bone métastases, was performed using the logrank test (18) . All p values given correspond to two-sided tests. Survival curves were estimated using the method of Kaplan and Meier (19) . Multivariate analysis was performed to assess the relationship between survival time and several variables simultaneously. For analyses of this type, the Cox's proportional hazards model was used. Potential subsets of variables were evaluated using the Score criterion and the final model was determined to be the most efficient model that maximizes this criteria. Variables adding little or no information were not included in the final models.
Results

Total survival
The overall 5-year and 10-year survival rate from the time of diagnosis of thyroid cancer (total survival) was 53% and 35%, respectively (Fig. 1 (Fig. 2) . Of the 75 (Fig. 4) .
In the multivariate model for survival from diagnosis of the initial bone metastasis with histology taken into account, undifferentiated, papillary, poorly differentiated, and follicular subtypes, as compared to Hürthle cell, were all additional negative prognostic variables for survival in that order ( (1) .
At time of diagnosis of the initial bone metastasis, age was not found to be a significant prognostic factor. This may be due to the small number of patients under 45 years of age in our study. The mean age of our patient cohort at diagnosis of initial bone metastasis was 58.7 years, which is higher than the average age of all patients with thyroid cancer at diagnosis (45 to 50 years) (1) . This age difference is consistent with previous reports (9, (13) (14) (15) (21) . The use of bisphosphonates, which reduce symptoms and complications of bone métastases in patients with metastatic breast cancer (22) and multiple myeloma (23) 
